

Ari M Melnick

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6259331/publications.pdf>

Version: 2024-02-01

424
papers

39,564
citations

2213

99
h-index

3260

185
g-index

428
all docs

428
docs citations

428
times ranked

47512
citing authors

#	ARTICLE	IF	CITATIONS
1	Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation. <i>Cancer Cell</i> , 2010, 18, 553-567.	7.7	2,328
2	IDH mutation impairs histone demethylation and results in a block to cell differentiation. <i>Nature</i> , 2012, 483, 474-478.	13.7	1,693
3	Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia. <i>New England Journal of Medicine</i> , 2012, 366, 1079-1089.	13.9	1,688
4	methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. <i>Genome Biology</i> , 2012, 13, R87.	13.9	1,541
5	Tet2 Loss Leads to Increased Hematopoietic Stem Cell Self-Renewal and Myeloid Transformation. <i>Cancer Cell</i> , 2011, 20, 11-24.	7.7	1,105
6	Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. <i>Nature Biotechnology</i> , 2010, 28, 848-855.	9.4	1,080
7	The N6-methyladenosine (m6A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. <i>Nature Medicine</i> , 2017, 23, 1369-1376.	15.2	971
8	A Molecular Roadmap of Reprogramming Somatic Cells into iPS Cells. <i>Cell</i> , 2012, 151, 1617-1632.	13.5	762
9	DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2010, 17, 13-27.	7.7	737
10	EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation. <i>Cancer Cell</i> , 2013, 23, 677-692.	7.7	706
11	Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. <i>Nature Genetics</i> , 2012, 44, 1179-1181.	9.4	692
12	The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight. <i>Science</i> , 2019, 364, .	6.0	576
13	The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. <i>Blood</i> , 2022, 140, 1229-1253.	0.6	512
14	ASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression. <i>Cancer Cell</i> , 2012, 22, 180-193.	7.7	504
15	IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. <i>Nature</i> , 2012, 488, 656-659.	13.7	474
16	DNMT1-interacting RNAs block gene-specific DNA methylation. <i>Nature</i> , 2013, 503, 371-376.	13.7	446
17	The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. <i>Nature Medicine</i> , 2015, 21, 1199-1208.	15.2	359
18	Comparative isoschizomer profiling of cytosine methylation: The HELP assay. <i>Genome Research</i> , 2006, 16, 1046-1055.	2.4	355

#	ARTICLE	IF	CITATIONS
19	Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2009, 27, 1209-1213.	0.8	322
20	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , 2016, 22, 792-799.	15.2	322
21	Loss of BAP1 function leads to EZH2-dependent transformation. <i>Nature Medicine</i> , 2015, 21, 1344-1349.	15.2	297
22	MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. <i>Blood</i> , 2009, 114, 3448-3458.	0.6	292
23	Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 8368-8373.	3.3	286
24	Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. <i>Nature Medicine</i> , 2004, 10, 1329-1335.	15.2	272
25	A Small-Molecule Inhibitor of BCL6 Kills DLBCL Cells In Vitro and In Vivo. <i>Cancer Cell</i> , 2010, 17, 400-411.	7.7	263
26	Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia. <i>PLoS Genetics</i> , 2012, 8, e1002781.	1.5	263
27	EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. <i>Blood</i> , 2010, 116, 5247-5255.	0.6	262
28	Mechanism of SMRT Corepressor Recruitment by the BCL6 BTB Domain. <i>Molecular Cell</i> , 2003, 12, 1551-1564.	4.5	251
29	Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. <i>Nature Chemical Biology</i> , 2011, 7, 818-826.	3.9	240
30	DNA Hydroxymethylation Profiling Reveals that WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. <i>Cell Reports</i> , 2014, 9, 1841-1855.	2.9	237
31	The epichaperome is an integrated chaperome network that facilitates tumour survival. <i>Nature</i> , 2016, 538, 397-401.	13.7	233
32	Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. <i>Nature Immunology</i> , 2007, 8, 705-714.	7.0	231
33	MALT1 Small Molecule Inhibitors Specifically Suppress ABC-DLBCL In Vitro and In Vivo. <i>Cancer Cell</i> , 2012, 22, 812-824.	7.7	229
34	Prolonged Administration of Azacitidine With or Without Entinostat for Myelodysplastic Syndrome and Acute Myeloid Leukemia With Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905. <i>Journal of Clinical Oncology</i> , 2014, 32, 1242-1248.	0.8	227
35	Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. <i>Blood</i> , 2012, 119, 5824-5831.	0.6	221
36	BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. <i>Journal of Experimental Medicine</i> , 2015, 212, 539-553.	4.2	218

#	ARTICLE	IF	CITATIONS
37	<i>CREBBP</i> Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. <i>Cancer Discovery</i> , 2017, 7, 38-53.	7.7	218
38	ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. <i>Cancer Cell</i> , 2018, 33, 495-511.e12.	7.7	216
39	Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. <i>Cancer Discovery</i> , 2019, 9, 546-563.	7.7	213
40	Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia. <i>Cancer Research</i> , 2014, 74, 2520-2532.	0.4	207
41	Translocations of the <i>RARα</i> gene in acute promyelocytic leukemia. <i>Oncogene</i> , 2001, 20, 7186-7203.	2.6	206
42	The <i>BCL6</i> transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. <i>Blood</i> , 2009, 113, 5536-5548.	0.6	205
43	Critical Residues within the BTB Domain of PLZF and Bcl-6 Modulate Interaction with Corepressors. <i>Molecular and Cellular Biology</i> , 2002, 22, 1804-1818.	1.1	200
44	The Leukemogenicity of AML1-ETO Is Dependent on Site-Specific Lysine Acetylation. <i>Science</i> , 2011, 333, 765-769.	6.0	200
45	EZH2 and <i>BCL6</i> Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. <i>Cancer Cell</i> , 2016, 30, 197-213.	7.7	200
46	DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. <i>Nature Medicine</i> , 2016, 22, 1488-1495.	15.2	195
47	Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2015, 27, 502-515.	7.7	191
48	Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. <i>Cancer Cell</i> , 2019, 36, 194-209.e9.	7.7	184
49	Mechanism-Based Epigenetic Chemosensitization Therapy of Diffuse Large B-Cell Lymphoma. <i>Cancer Discovery</i> , 2013, 3, 1002-1019.	7.7	180
50	<i>BCL6</i> enables Ph ⁺ acute lymphoblastic leukaemia cells to survive BCR α -ABL1 kinase inhibition. <i>Nature</i> , 2011, 473, 384-388.	13.7	174
51	The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2015, 125, 13-21.	0.6	168
52	The Promyelocytic Leukemia Zinc Finger Protein Affects Myeloid Cell Growth, Differentiation, and Apoptosis. <i>Molecular and Cellular Biology</i> , 1998, 18, 5533-5545.	1.1	164
53	Structural Architecture of the CARMA1/Bcl10/MALT1 Signalosome: Nucleation-Induced Filamentous Assembly. <i>Molecular Cell</i> , 2013, 51, 766-779.	4.5	163
54	A Hybrid Mechanism of Action for <i>BCL6</i> in B Cells Defined by Formation of Functionally Distinct Complexes at Enhancers and Promoters. <i>Cell Reports</i> , 2013, 4, 578-588.	2.9	161

#	ARTICLE	IF	CITATIONS
55	Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. <i>Nature</i> , 2021, 589, 299-305.	13.7	155
56	A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. <i>Blood</i> , 2009, 113, 3397-3405.	0.6	154
57	BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. <i>Journal of Experimental Medicine</i> , 2011, 208, 2163-2174.	4.2	154
58	CTCF Haploinsufficiency Destabilizes DNA Methylation and Predisposes to Cancer. <i>Cell Reports</i> , 2014, 7, 1020-1029.	2.9	154
59	The Eph-Receptor A7 Is a Soluble Tumor Suppressor for Follicular Lymphoma. <i>Cell</i> , 2011, 147, 554-564.	13.5	151
60	Epigenetic Repression of miR-31 Disrupts Androgen Receptor Homeostasis and Contributes to Prostate Cancer Progression. <i>Cancer Research</i> , 2013, 73, 1232-1244.	0.4	150
61	A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. <i>Nature Medicine</i> , 2009, 15, 1369-1376.	15.2	149
62	Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. <i>Trends in Molecular Medicine</i> , 2014, 20, 343-352.	3.5	148
63	The therapeutic landscape for cells engineered with chimeric antigen receptors. <i>Nature Biotechnology</i> , 2020, 38, 233-244.	9.4	147
64	Kaiso-Deficient Mice Show Resistance to Intestinal Cancer. <i>Molecular and Cellular Biology</i> , 2006, 26, 199-208.	1.1	146
65	Structure of a BCOR Corepressor Peptide in Complex with the BCL6 BTB Domain Dimer. <i>Molecular Cell</i> , 2008, 29, 384-391.	4.5	144
66	Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. <i>Science Translational Medicine</i> , 2016, 8, 366ra161.	5.8	144
67	An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. <i>Cancer Cell</i> , 2021, 39, 240-256.e11.	7.7	143
68	Oncogene-mediated alterations in chromatin conformation. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 9083-9088.	3.3	142
69	High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. <i>Nucleic Acids Research</i> , 2009, 37, 3829-3839.	6.5	141
70	Pathogenic role of B-cell receptor signaling and canonical NF- κ B activation in mantle cell lymphoma. <i>Blood</i> , 2016, 128, 82-92.	0.6	141
71	Notch activation inhibits AML growth and survival: a potential therapeutic approach. <i>Journal of Experimental Medicine</i> , 2013, 210, 321-337.	4.2	139
72	Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. <i>Blood</i> , 2010, 116, 1025-1034.	0.6	138

#	ARTICLE	IF	CITATIONS
73	DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. <i>Blood</i> , 2010, 116, e81-e89.	0.6	138
74	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. <i>Journal of Experimental Medicine</i> , 2015, 212, 1819-1832.	4.2	137
75	Induction of sarcomas by mutant IDH2. <i>Genes and Development</i> , 2013, 27, 1986-1998.	2.7	135
76	The ETO Protein Disrupted in t(8;21)-Associated Acute Myeloid Leukemia Is a Corepressor for the Promyelocytic Leukemia Zinc Finger Protein. <i>Molecular and Cellular Biology</i> , 2000, 20, 2075-2086.	1.1	134
77	A stable transcription factor complex nucleated by oligomeric AML1 α ETO controls leukaemogenesis. <i>Nature</i> , 2013, 500, 93-97.	13.7	134
78	The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. <i>Clinical Cancer Research</i> , 2017, 23, 885-893.	3.2	133
79	Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. <i>Cancer Discovery</i> , 2021, 11, 1542-1561.	7.7	133
80	Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 3351-3362.	3.9	133
81	EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. <i>Nature Communications</i> , 2017, 8, 877.	5.8	132
82	Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. <i>Nature Communications</i> , 2021, 12, 1660.	5.8	132
83	Histone deacetylase inhibitor treatment induces α -BRCAness α ™ and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. <i>Oncotarget</i> , 2014, 5, 5637-5650.	0.8	131
84	Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 3207-3212.	3.3	130
85	Genetic and epigenetic heterogeneity in acute myeloid leukemia. <i>Current Opinion in Genetics and Development</i> , 2016, 36, 100-106.	1.5	130
86	A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. <i>Molecular Cell</i> , 2016, 63, 711-719.	4.5	128
87	Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. <i>Nature</i> , 2015, 521, 357-361.	13.7	127
88	DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. <i>Blood</i> , 2011, 118, 3559-3569.	0.6	123
89	TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2018, 8, 1632-1653.	7.7	120
90	Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. <i>Cancer Discovery</i> , 2021, 11, 1468-1489.	7.7	119

#	ARTICLE	IF	CITATIONS
91	Whole-genome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. <i>Genome Research</i> , 2015, 25, 478-487.	2.4	118
92	BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. <i>Blood</i> , 2007, 110, 2067-2074.	0.6	117
93	Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. <i>Journal of Clinical Investigation</i> , 2013, 123, 3099-3111.	3.9	115
94	Germinal center-derived lymphomas: The darkest side of humoral immunity. <i>Immunological Reviews</i> , 2019, 288, 214-239.	2.8	113
95	Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. <i>Immunity</i> , 2016, 45, 497-512.	6.6	112
96	Widespread Hypomethylation Occurs Early and Synergizes with Gene Amplification during Esophageal Carcinogenesis. <i>PLoS Genetics</i> , 2011, 7, e1001356.	1.5	112
97	The Bcl6-SMRT/NCOR Cistrome Represses Inflammation to Attenuate Atherosclerosis. <i>Cell Metabolism</i> , 2012, 15, 554-562.	7.2	111
98	Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. <i>Nature Immunology</i> , 2013, 14, 380-388.	7.0	111
99	Epigenomic evolution in diffuse large B-cell lymphomas. <i>Nature Communications</i> , 2015, 6, 6921.	5.8	111
100	Self-Enforcing Feedback Activation between BCL6 and Pre-B Cell Receptor Signaling Defines a Distinct Subtype of Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 27, 409-425.	7.7	109
101	Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. <i>Blood</i> , 2010, 115, 4798-4809.	0.6	108
102	BCL6 is critical for the development of a diverse primary B cell repertoire. <i>Journal of Experimental Medicine</i> , 2010, 207, 1209-1221.	4.2	108
103	Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015, 28, 114-128.	7.7	107
104	Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. <i>Cancer Discovery</i> , 2020, 10, 440-459.	7.7	103
105	Aberration in DNA Methylation in B-Cell Lymphomas Has a Complex Origin and Increases with Disease Severity. <i>PLoS Genetics</i> , 2013, 9, e1003137.	1.5	102
106	Hematopoietic Stem Cell Origin of <i>BRAF</i> V600E Mutations in Hairy Cell Leukemia. <i>Science Translational Medicine</i> , 2014, 6, 238ra71.	5.8	102
107	Histone deacetylases as therapeutic targets in hematologic malignancies. <i>Current Opinion in Hematology</i> , 2002, 9, 322-332.	1.2	101
108	Kaiso Contributes to DNA Methylation-Dependent Silencing of Tumor Suppressor Genes in Colon Cancer Cell Lines. <i>Cancer Research</i> , 2008, 68, 7258-7263.	0.4	101

#	ARTICLE	IF	CITATIONS
109	Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. <i>Cancer Discovery</i> , 2017, 7, 868-883.	7.7	101
110	H1 histones control the epigenetic landscape by local chromatin compaction. <i>Nature</i> , 2021, 589, 293-298.	13.7	101
111	BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. <i>Journal of Clinical Investigation</i> , 2010, 120, 4569-4582.	3.9	101
112	BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. <i>Nature Medicine</i> , 2013, 19, 1014-1022.	15.2	100
113	Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. <i>Blood</i> , 2011, 117, 234-241.	0.6	94
114	PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. <i>Nature Medicine</i> , 2016, 22, 379-387.	15.2	94
115	Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in <i>IDH2</i> - and <i>TET2</i> -Mutant Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2017, 7, 494-505.	7.7	94
116	SYK inhibition and response prediction in diffuse large B-cell lymphoma. <i>Blood</i> , 2011, 118, 6342-6352.	0.6	93
117	DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at <i>Alu</i> elements during B-cell activation. <i>Genome Research</i> , 2013, 23, 2030-2041.	2.4	93
118	Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. <i>Cancer Cell</i> , 2020, 37, 655-673.e11.	7.7	93
119	Genome-wide analysis of DNA binding and transcriptional regulation by the mammalian Doublesex homolog DMRT1 in the juvenile testis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13360-13365.	3.3	92
120	Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. <i>Nature Immunology</i> , 2013, 14, 437-445.	7.0	92
121	Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation. <i>Blood</i> , 2014, 123, 1012-1020.	0.6	89
122	Enhanced Reduced Representation Bisulfite Sequencing for Assessment of DNA Methylation at Base Pair Resolution. <i>Journal of Visualized Experiments</i> , 2015, , e52246.	0.2	89
123	Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. <i>Journal of Clinical Investigation</i> , 2015, 125, 1286-1298.	3.9	89
124	DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. <i>Cell Reports</i> , 2015, 12, 2086-2098.	2.9	87
125	BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. <i>Blood Cells, Molecules, and Diseases</i> , 2008, 41, 95-99.	0.6	84
126	The Impact of Heterogeneity on Single-Cell Sequencing. <i>Frontiers in Genetics</i> , 2019, 10, 8.	1.1	84

#	ARTICLE	IF	CITATIONS
127	Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. <i>Blood</i> , 2009, 113, 2795-2804.	0.6	83
128	Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. <i>Blood</i> , 2014, 123, 1699-1708.	0.6	83
129	Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia. <i>Cancer Discovery</i> , 2012, 2, 1004-1023.	7.7	80
130	Emerging epigenetic-modulating therapies in lymphoma. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 494-507.	12.5	80
131	Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, E2219-28.	3.3	78
132	PRMT4 Blocks Myeloid Differentiation by Assembling a Methyl-RUNX1-Dependent Repressor Complex. <i>Cell Reports</i> , 2013, 5, 1625-1638.	2.9	77
133	Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12697-12702.	3.3	77
134	An Integrative Genomic and Epigenomic Approach for the Study of Transcriptional Regulation. <i>PLoS ONE</i> , 2008, 3, e1882.	1.1	77
135	Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs. <i>Molecular Cell</i> , 2015, 59, 89-103.	4.5	76
136	Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. <i>Blood</i> , 2016, 127, 858-868.	0.6	76
137	Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. <i>Blood</i> , 2013, 121, 5192-5202.	0.6	75
138	Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. <i>Nature Genetics</i> , 2017, 49, 866-875.	9.4	75
139	CG dinucleotide clustering is a species-specific property of the genome. <i>Nucleic Acids Research</i> , 2007, 35, 6798-6807.	6.5	74
140	Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. <i>Nature Communications</i> , 2014, 5, 3904.	5.8	73
141	DNMT3A Haploinsufficiency Transforms FLT3-ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2016, 6, 501-515.	7.7	73
142	Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. <i>Nature Communications</i> , 2019, 10, 821.	5.8	73
143	B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. <i>Current Opinion in Hematology</i> , 2008, 15, 381-390.	1.2	71
144	Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. <i>Cancer Cell</i> , 2018, 33, 44-59.e8.	7.7	71

#	ARTICLE	IF	CITATIONS
145	Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. <i>Nature Immunology</i> , 2019, 20, 86-96.	7.0	71
146	ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. <i>Blood</i> , 2004, 103, 1454-1463.	0.6	70
147	Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. <i>Cancer Cell</i> , 2019, 35, 916-931.e9.	7.7	70
148	Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. <i>Cancer Cell</i> , 2019, 36, 402-417.e13.	7.7	69
149	The BCL6 RD2 Domain Governs Commitment of Activated B Cells to Form Germinal Centers. <i>Cell Reports</i> , 2014, 8, 1497-1508.	2.9	67
150	Dynamic evolution of clonal epialleles revealed by methclone. <i>Genome Biology</i> , 2014, 15, 472.	3.8	67
151	Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. <i>Biomaterials</i> , 2015, 73, 110-119.	5.7	66
152	Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. <i>Nature Communications</i> , 2019, 10, 1874.	5.8	63
153	TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. <i>Cell</i> , 2020, 182, 297-316.e27.	13.5	63
154	Downregulation of FOXP1 is required during germinal center B-cell function. <i>Blood</i> , 2013, 121, 4311-4320.	0.6	62
155	Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma. <i>Genome Medicine</i> , 2015, 7, 110.	3.6	62
156	SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. <i>Blood</i> , 2013, 121, 148-155.	0.6	61
157	Epigenetics and B-cell lymphoma. <i>Current Opinion in Hematology</i> , 2011, 18, 293-299.	1.2	60
158	MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2018, 8, 478-497.	7.7	59
159	Molecular classification improves risk assessment in adult <i>BCR-ABL1</i> negative B-ALL. <i>Blood</i> , 2021, 138, 948-958.	0.6	59
160	BCL6 modulates tissue neutrophil survival and exacerbates pulmonary inflammation following influenza virus infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11888-11893.	3.3	58
161	New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. <i>Current Opinion in Immunology</i> , 2013, 25, 339-346.	2.4	57
162	DNMT3B7, a Truncated DNMT3B Isoform Expressed in Human Tumors, Disrupts Embryonic Development and Accelerates Lymphomagenesis. <i>Cancer Research</i> , 2010, 70, 5840-5850.	0.4	56

#	ARTICLE	IF	CITATIONS
163	SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. <i>Cancer Research</i> , 2016, 76, 5467-5478.	0.4	55
164	PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. <i>Blood</i> , 2019, 133, 2401-2412.	0.6	54
165	CtBP Is an Essential Corepressor for BCL6 Autoregulation. <i>Molecular and Cellular Biology</i> , 2008, 28, 2175-2186.	1.1	53
166	BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. <i>Blood</i> , 2009, 114, 5315-5321.	0.6	53
167	Negative regulation of osteoclast precursor differentiation by CD11b and $\alpha 2$ integrin-B-cell lymphoma 6 signaling. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 135-149.	3.1	52
168	Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. <i>Blood</i> , 2014, 123, 3327-3335.	0.6	52
169	Genetic and epigenetic inactivation of <i>SESTRIN1</i> controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	52
170	A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. <i>Cell Reports</i> , 2015, 13, 2159-2173.	2.9	51
171	AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. <i>Nature Communications</i> , 2018, 9, 222.	5.8	51
172	Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. <i>Journal of Clinical Investigation</i> , 2018, 128, 4397-4412.	3.9	51
173	Methylome Profiling Reveals Distinct Alterations in Phenotypic and Mutational Subgroups of Myeloproliferative Neoplasms. <i>Cancer Research</i> , 2013, 73, 1076-1085.	0.4	50
174	C/EBP β deregulation results in differentiation arrest in acute myeloid leukemia. <i>Journal of Clinical Investigation</i> , 2012, 122, 4490-4504.	3.9	50
175	Central role of myeloid MCP1 in protecting against LPS-induced inflammation and lung injury. <i>Signal Transduction and Targeted Therapy</i> , 2017, 2, 17066.	7.1	48
176	PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. <i>Blood</i> , 2018, 132, 2026-2039.	0.6	48
177	The Epigenetic Basis of Diffuse Large B-Cell Lymphoma. <i>Seminars in Hematology</i> , 2015, 52, 86-96.	1.8	47
178	Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing. <i>Nature Biotechnology</i> , 2022, 40, 1488-1499.	9.4	46
179	Inhibition of Anaplastic Lymphoma Kinase (ALK) Activity Provides a Therapeutic Approach for CLTC-ALK-Positive Human Diffuse Large B Cell Lymphomas. <i>PLoS ONE</i> , 2011, 6, e18436.	1.1	45
180	Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. <i>Best Practice and Research in Clinical Haematology</i> , 2003, 16, 387-408.	0.7	44

#	ARTICLE	IF	CITATIONS
181	Genome-Wide Detection of Genes Targeted by Non-Ig Somatic Hypermutation in Lymphoma. PLoS ONE, 2012, 7, e40332.	1.1	44
182	BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer Discovery, 2017, 7, 506-521.	7.7	43
183	The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood, 2004, 103, 4650-4658.	0.6	42
184	Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature Communications, 2016, 7, 11889.	5.8	42
185	Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leukemia and Lymphoma, 2008, 49, 874-882.	0.6	41
186	Aberrant Epigenetic and Genetic Marks Are Seen in Myelodysplastic Leukocytes and Reveal Dock4 as a Candidate Pathogenic Gene on Chromosome 7q. Journal of Biological Chemistry, 2011, 286, 25211-25223.	1.6	41
187	Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nature Communications, 2015, 6, 6471.	5.8	41
188	MALT1 Inhibition Is Efficacious in Both Na ⁺ -ve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. Cancer Research, 2017, 77, 7038-7048.	0.4	41
189	Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood, 2008, 112, 644-651.	0.6	40
190	Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood, 2012, 119, 5478-5491.	0.6	39
191	H2.0-like Homeobox Regulates Early Hematopoiesis and Promotes Acute Myeloid Leukemia. Cancer Cell, 2012, 22, 194-208.	7.7	39
192	LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. British Journal of Haematology, 2013, 162, 621-630.	1.2	39
193	Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood, 2018, 132, 1265-1278.	0.6	39
194	Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells. Biomaterials, 2019, 198, 27-36.	5.7	39
195	BCL6-mediated Attenuation of DNA Damage Sensing Triggers Growth Arrest and Senescence through a p53-dependent Pathway in a Cell Context-dependent Manner. Journal of Biological Chemistry, 2008, 283, 22565-22572.	1.6	38
196	HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. Journal of Clinical Investigation, 2014, 124, 1158-1167.	3.9	38
197	Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. Cellular and Molecular Bioengineering, 2014, 7, 394-408.	1.0	37
198	miR-181a negatively regulates NF- κ B signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis. Blood, 2016, 127, 2856-2866.	0.6	37

#	ARTICLE	IF	CITATIONS
199	Multi-omic, Single-Cell, and Biochemical Profiles of Astronauts Guide Pharmacological Strategies for Returning to Gravity. <i>Cell Reports</i> , 2020, 33, 108429.	2.9	37
200	Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2015, 125, 4559-4571.	3.9	37
201	Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. <i>Cancer Discovery</i> , 2019, 9, 872-889.	7.7	36
202	Mechanisms of action of BCL6 during germinal center B cell development. <i>Science China Life Sciences</i> , 2015, 58, 1226-1232.	2.3	35
203	The many layers of epigenetic dysfunction in B-cell lymphomas. <i>Current Opinion in Hematology</i> , 2016, 23, 377-384.	1.2	35
204	Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7573-7588.	2.9	35
205	Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development. <i>Cell Reports</i> , 2020, 33, 108448.	2.9	35
206	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. <i>Genome Research</i> , 2020, 30, 1217-1227.	2.4	35
207	The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. <i>Nature Cancer</i> , 2020, 1, 653-664.	5.7	35
208	NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biological Considerations of Hematological Relapse following Allogeneic Stem Cell Transplantation Unrelated to Graft-versus-Tumor Effects: State of the Science. <i>Biology of Blood and Marrow Transplantation</i> , 2010, 16, 709-728.	2.0	34
209	BCL6-Mediated Survival Signaling Promotes Drug-Resistance in BCRABL1- Driven Acute Lymphoblastic Leukemia. <i>Blood</i> , 2008, 112, 295-295.	0.6	34
210	KDM5 inhibition offers a novel therapeutic strategy for the treatment of <i>KMT2D</i> mutant lymphomas. <i>Blood</i> , 2021, 138, 370-381.	0.6	33
211	BCL6 breaks occur at different AID sequence motifs in Ig α -BCL6 and non-Ig α -BCL6 rearrangements. <i>Blood</i> , 2013, 121, 4551-4554.	0.6	32
212	The Theoretical Basis of Transcriptional Therapy of Cancer: Can It Be Put Into Practice?. <i>Journal of Clinical Oncology</i> , 2005, 23, 3957-3970.	0.8	31
213	BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. <i>Cancer Discovery</i> , 2019, 9, 662-679.	7.7	31
214	Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. <i>IScience</i> , 2020, 23, 101844.	1.9	31
215	Sequential Transcription Factor Targeting for Diffuse Large B-Cell Lymphomas. <i>Cancer Research</i> , 2008, 68, 3361-3369.	0.4	30
216	SAFB1 Mediates Repression of Immune Regulators and Apoptotic Genes in Breast Cancer Cells. <i>Journal of Biological Chemistry</i> , 2010, 285, 3608-3616.	1.6	30

#	ARTICLE	IF	CITATIONS
217	How Biophysical Forces Regulate Human B Cell Lymphomas. <i>Cell Reports</i> , 2018, 23, 499-511.	2.9	30
218	Clonal Hematopoiesis Before, During, and After Human Spaceflight. <i>Cell Reports</i> , 2020, 33, 108458.	2.9	30
219	Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , 2012, 51, 1125-1132.	1.5	29
220	TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. <i>Science Advances</i> , 2020, 6, eaay5872.	4.7	29
221	DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. <i>Nature Communications</i> , 2021, 12, 5406.	5.8	29
222	Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	29
223	Specific peptides for the therapeutic targeting of oncogenes. <i>Current Opinion in Genetics and Development</i> , 2006, 16, 71-77.	1.5	28
224	Inhibition of DNA Methyltransferase Activates Tumor Necrosis Factor α -Induced Monocytic Differentiation in Acute Myeloid Leukemia Cells. <i>Cancer Research</i> , 2009, 69, 55-64.	0.4	28
225	Epigenetics in AML. <i>Best Practice and Research in Clinical Haematology</i> , 2010, 23, 463-468.	0.7	28
226	Modular Immune Organoids with Integrin Ligand Specificity Differentially Regulate Ex Vivo B Cell Activation. <i>ACS Biomaterials Science and Engineering</i> , 2017, 3, 214-225.	2.6	28
227	MTA2/NuRD Regulates B Cell Development and Cooperates with OCA-B in Controlling the Pre-B to Immature B Cell Transition. <i>Cell Reports</i> , 2019, 28, 472-485.e5.	2.9	28
228	Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. <i>Blood Advances</i> , 2020, 4, 5226-5231.	2.5	28
229	Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. <i>Leukemia</i> , 2021, 35, 1438-1450.	3.3	28
230	North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age \geq 60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906). <i>Blood</i> , 2015, 126, 217-217.	0.6	28
231	Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 88, 231-245.	2.0	26
232	Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. <i>Oncotarget</i> , 2016, 7, 3520-3532.	0.8	26
233	Intravital three-photon microscopy allows visualization over the entire depth of mouse lymph nodes. <i>Nature Immunology</i> , 2022, 23, 330-340.	7.0	26
234	Expression of p21 Protein Predicts Clinical Outcome in DLBCL Patients Older than 60 Years Treated with R-CHOP but not CHOP: A Prospective ECOG and Southwest Oncology Group Correlative Study on E4494. <i>Clinical Cancer Research</i> , 2010, 16, 2435-2442.	3.2	25

#	ARTICLE	IF	CITATIONS
235	The dangers of dÃ©jÃ© vu: memory B cells as the cells of origin of ABC-DLBCLs. <i>Blood</i> , 2020, 136, 2263-2274.	0.6	25
236	Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. <i>Nature Immunology</i> , 2021, 22, 240-253.	7.0	24
237	System-wide transcriptome damage and tissue identity loss in COVID-19 patients. <i>Cell Reports Medicine</i> , 2022, 3, 100522.	3.3	24
238	Epigenetic Therapy Leaps Ahead with Specific Targeting of EZH2. <i>Cancer Cell</i> , 2012, 22, 569-570.	7.7	23
239	Molecular Pathways: Targeting MALT1 Paracaspase Activity in Lymphoma. <i>Clinical Cancer Research</i> , 2013, 19, 6662-6668.	3.2	23
240	Affinity Purification Probes of Potential Use To Investigate the Endogenous Hsp70 Interactome in Cancer. <i>ACS Chemical Biology</i> , 2014, 9, 1698-1705.	1.6	23
241	Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML. <i>Cancer Discovery</i> , 2020, 10, 1934-1949.	7.7	23
242	EZH2 and BCL6 Cooperate To Create The Germinal Center B-Cell Phenotype and Induce Lymphomas Through Formation and Repression Of Bivalent Chromatin Domains. <i>Blood</i> , 2013, 122, 1-1.	0.6	23
243	Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. <i>Blood</i> , 2021, 137, 788-800.	0.6	22
244	AG-221, a Small Molecule Mutant IDH2 Inhibitor, Remodels the Epigenetic State of IDH2-Mutant Cells and Induces Alterations in Self-Renewal/Differentiation in IDH2-Mutant AML Model in Vivo. <i>Blood</i> , 2014, 124, 437-437.	0.6	22
245	Mutant <i>IDH</i> : a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. <i>Epigenomics</i> , 2016, 8, 945-957.	1.0	21
246	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 94-99.	0.6	21
247	Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage. <i>Molecular Cell</i> , 2020, 80, 845-861.e10.	4.5	21
248	An Autochthonous Mouse Model of <i>Myd88</i> - and <i>BCL2</i> -Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. <i>Blood Cancer Discovery</i> , 2021, 2, 70-91.	2.6	21
249	Dynamic Changes Of DNA Methylation and a Functional Role For TET2 DNA Dioxygenase In Human Erythroid Differentiation. <i>Blood</i> , 2013, 122, 3415-3415.	0.6	21
250	Meta-Analysis of Microarray Studies Reveals a Novel Hematopoietic Progenitor Cell Signature and Demonstrates Feasibility of Inter-Platform Data Integration. <i>PLoS ONE</i> , 2008, 3, e2965.	1.1	20
251	The SEQC2 epigenomics quality control (EpiQC) study. <i>Genome Biology</i> , 2021, 22, 332.	3.8	20
252	A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. <i>JCI Insight</i> , 2016, 1, .	2.3	19

#	ARTICLE	IF	CITATIONS
253	A roadmap for discovery and translation in lymphoma. <i>Blood</i> , 2015, 125, 2175-2177.	0.6	18
254	Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. <i>Blood</i> , 2017, 129, 1779-1790.	0.6	18
255	BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. <i>Blood</i> , 2021, 137, 812-825.	0.6	18
256	Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?. Expert Review of Hematology, 2013, 6, 343-345.	1.0	17
257	Rationale for targeting BCL6 in <i>MLL</i> -rearranged acute lymphoblastic leukemia. <i>Genes and Development</i> , 2019, 33, 1265-1279.	2.7	17
258	Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4333-4358.	2.9	16
259	Peptide-based covalent inhibitors of MALT1 paracaspase. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1336-1339.	1.0	15
260	Quinoline and thiazolopyridine allosteric inhibitors of MALT1. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 1694-1698.	1.0	14
261	Epigenetic Mechanisms in Leukemias and Lymphomas. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 10, a034959.	2.9	14
262	Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival. <i>Blood Cancer Discovery</i> , 2022, 3, 50-65.	2.6	14
263	SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermethylation to Drive B-cell Lymphomagenesis. <i>Cancer Discovery</i> , 2022, 12, 1782-1803.	7.7	14
264	Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model. <i>Cancer Research</i> , 2017, 77, 1818-1830.	0.4	13
265	Allele-specific expression of <i>GATA2</i> due to epigenetic dysregulation in <i>CEBPA</i> double-mutant AML. <i>Blood</i> , 2021, 138, 160-177.	0.6	13
266	In-Depth Mutational Analysis of the Promyelocytic Leukemia Zinc Finger BTB/POZ Domain Reveals Motifs and Residues Required for Biological and Transcriptional Functions. <i>Molecular and Cellular Biology</i> , 2000, 20, 6550-6567.	1.1	13
267	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabb7695.	5.8	13
268	Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 789-798.	0.6	12
269	Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. <i>Journal of Clinical Investigation</i> , 2022, 132, .	3.9	12
270	Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. <i>Hematological Oncology</i> , 2017, 35, 397-407.	0.8	11

#	ARTICLE	IF	CITATIONS
271	Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. <i>Leukemia</i> , 2021, 35, 3012-3016.	3.3	11
272	OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity. <i>Nature Immunology</i> , 2021, 22, 1327-1340.	7.0	11
273	Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer. <i>Cancer Research</i> , 2021, 81, 6061-6070.	0.4	11
274	Therapeutic Targeting of Lymphoma-Associated Vascular Pericytes,. <i>Blood</i> , 2011, 118, 3725-3725.	0.6	11
275	The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. <i>PLoS ONE</i> , 2020, 15, e0231470.	1.1	10
276	Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). <i>Current Cancer Drug Targets</i> , 2021, 21, 274-282.	0.8	10
277	ABC and GCB DLBCLs Display Unique Biologically Distinct and Clinically Relevant Epigenetic Signatures.. <i>Blood</i> , 2009, 114, 619-619.	0.6	10
278	SIRT3 Is a Novel Metabolic Driver of and Therapeutic Target for Chemotherapy Resistant Dlbcls. <i>Blood</i> , 2017, 130, 643-643.	0.6	9
279	Differentiation therapy for IDH1/2 mutant malignancies. <i>Cell Research</i> , 2013, 23, 975-977.	5.7	8
280	An Esrrb and Nanog Cell Fate Regulatory Module Controlled by Feed Forward Loop Interactions. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 630067.	1.8	8
281	Epigenetic Determinants of Pathogenesis and Resistance to Proteasome Inhibition in Mantle Cell Lymphoma.. <i>Blood</i> , 2008, 112, 3373-3373.	0.6	8
282	VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma. <i>Journal of Visualized Experiments</i> , 2015, , e53215.	0.2	7
283	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , 2016, 22, 578-579.	15.2	7
284	DNA Methylation-Based Biomarkers. <i>Journal of Clinical Oncology</i> , 2017, 35, 793-795.	0.8	7
285	Role of chromosomal architecture in germinal center B cells and lymphomagenesis. <i>Current Opinion in Hematology</i> , 2019, 26, 294-302.	1.2	7
286	Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. <i>Leukemia</i> , 2021, 35, 2688-2692.	3.3	7
287	Importance of Achieving Complete Remission (CR) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults Age ≥60 Years: Analysis of Risk Factors for Early Mortality and Re-Induction, and Impact of Quality of Response on Overall Survival (OS) in the ECOG-ACRIN E2906 Randomized Trial. <i>Blood</i> , 2016, 128, 339-339.	0.6	7
288	Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 805195.	1.8	7

#	ARTICLE	IF	CITATIONS
289	Reprogramming Specific Gene Expression Pathways in B-Cell Lymphomas. <i>Cell Cycle</i> , 2005, 4, 241-243.	1.3	6
290	Histone 1 Mutations Drive Lymphomagenesis By Inducing Primitive Stem Cell Functions and Epigenetic Instructions through Profound 3D Re-Organization of the B-Cell Genome. <i>Blood</i> , 2019, 134, 23-23.	0.6	6
291	CD25 (IL2RA) Orchestrates Negative Feedback Control and Stabilizes Oncogenic Signaling Strength in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2015, 126, 1434-1434.	0.6	6
292	The Histone Demethylase LSD1 Acts As a BCL6 Corepressor In Germinal Center B Cells. <i>Blood</i> , 2013, 122, 781-781.	0.6	6
293	Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. <i>Blood Reviews</i> , 2022, 56, 100988.	2.8	6
294	Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. <i>Frontiers in Immunology</i> , 2021, 12, 688493.	2.2	5
295	Conformational transitions in BTC1 antiproliferative protein and their modulation by disease mutants. <i>Biophysical Journal</i> , 2022, 121, 3753-3764.	0.2	5
296	An "EZ" Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?. <i>Cancer Discovery</i> , 2019, 9, 1158-1160.	7.7	4
297	Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. <i>IScience</i> , 2021, 24, 102651.	1.9	4
298	BCL10 Gain-of-Function Mutations Aberrantly Induce Canonical and Non-Canonical NF-Kb Activation and Resistance to Ibrutinib in ABC-DLBCL. <i>Blood</i> , 2020, 136, 2-3.	0.6	4
299	High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial. <i>Blood</i> , 2010, 116, 851-851.	0.6	4
300	ASXL1 Mutations Promote Myeloid Transformation Through Inhibition of PRC2-Mediated Gene Repression. <i>Blood</i> , 2011, 118, 405-405.	0.6	4
301	Targeting Lymphomas Through MALT1 Inhibition. <i>Oncotarget</i> , 2012, 3, 1493-1494.	0.8	4
302	BCL6-Mediated Repression of p53 Is Critical for Leukemia Stem Cell Survival in Chronic Myeloid Leukemia. <i>Blood</i> , 2011, 118, 446-446.	0.6	4
303	Diverging regulation of Bach2 protein and RNA expression determine cell fate in early B cell response. <i>Cell Reports</i> , 2022, 40, 111035.	2.9	4
304	Discovering What Makes STAT Signaling TYK in T-ALL. <i>Cancer Discovery</i> , 2013, 3, 494-496.	7.7	3
305	Untangling the Role of Polycomb Complexes in Chemotherapy Resistance. <i>Cancer Discovery</i> , 2018, 8, 1348-1351.	7.7	3
306	The Role of Epigenetic Mechanisms in B Cell Lymphoma Pathogenesis. <i>Annual Review of Cancer Biology</i> , 2021, 5, 311-330.	2.3	3

#	ARTICLE	IF	CITATIONS
307	Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia. <i>Blood Cancer Discovery</i> , 2021, 2, 198-200.	2.6	3
308	Two Different EVI1 Expressing Poor-Risk AML Subgroups with Distinct Epigenetic Signatures Uncovered by Genome Wide DNA Methylation Profiling. <i>Blood</i> , 2008, 112, 757-757.	0.6	3
309	BCL6 Mediates a Stress Tolerance Phenotype through Its BTB Domain. <i>Blood</i> , 2014, 124, 567-567.	0.6	3
310	Chemically Induced Degradation of MALT1 to Treat B-Cell Lymphomas. <i>Blood</i> , 2019, 134, 2073-2073.	0.6	3
311	EZH2 Gain-of-Function Mutations Generate a Lymphoma-Permissive Immune Niche. <i>Blood</i> , 2019, 134, 2768-2768.	0.6	3
312	Targeted detection and quantitation of histone modifications from 1,000 cells. <i>PLoS ONE</i> , 2020, 15, e0240829.	1.1	3
313	General Biomarker Recommendations for Lymphoma. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw250.	3.0	2
314	Dissecting bulk transcriptomes of diffuse large B cell lymphoma. <i>Cancer Cell</i> , 2021, 39, 1305-1307.	7.7	2
315	Epigenetic Signatures Identify New Clinically Relevant Subtypes and Define Gene Regulatory Patterns in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2008, 112, 756-756.	0.6	2
316	Epigenomic Evolution In Diffuse Large B-Cell Lymphomas. <i>Blood</i> , 2013, 122, 634-634.	0.6	2
317	Targeting BCL6 and Germinal Centers (GCs) in Chronic Graft-Versus-Host Disease (cGVHD) Using Direct and Epigenomic Therapies. <i>Blood</i> , 2014, 124, 535-535.	0.6	2
318	A Virtual B Cell Lymphoma Model to Predict Effective Combination Therapy. <i>Blood</i> , 2014, 124, 928-928.	0.6	2
319	Divergent Dynamics of Epigenetic and Genetic Heterogeneity in Relapsed Acute Myeloid Leukemia. <i>Blood</i> , 2015, 126, 306-306.	0.6	2
320	CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies. <i>Blood</i> , 2016, 128, 4088-4088.	0.6	2
321	Myelodysplastic Syndrome (MDS) Displays Profound and Functionally Significant Epigenetic Deregulation Compared to Acute Myeloid Leukemia (AML) and Normal Bone Marrow Cells.. <i>Blood</i> , 2007, 110, 345-345.	0.6	2
322	EZH2 Mediates DNA Methylation-Independent Epigenetic Silencing of a Germinal Center Specific Transcriptional Program That Contributes to Cellular Proliferation and Lymphomagenesis.. <i>Blood</i> , 2009, 114, 3465-3465.	0.6	2
323	BCL6 Is Required for Leukemia-Initiation and Self-Renewal Signaling in Chronic Myeloid Leukemia.. <i>Blood</i> , 2009, 114, 2167-2167.	0.6	2
324	MALT1 Degradation with a Proteolysis-Targeting Chimera for the Treatment of Activated B-Cell Type Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 269-269.	0.6	2

#	ARTICLE	IF	CITATIONS
325	BTG1 Mutation Promotes Aggressive Lymphoma Development By Lowering the Threshold to MYC Activation and Generating "Super-Competitor" B Cells. <i>Blood</i> , 2021, 138, 359-359.	0.6	2
326	Histone 3 Methyltransferases Alter Melanoma Initiation and Progression Through Discrete Mechanisms. <i>Frontiers in Cell and Developmental Biology</i> , 2022, 10, 814216.	1.8	2
327	Loss of function mutations of <i>BCOR</i> in classical Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2022, 63, 1080-1090.	0.6	2
328	3D chromosomal architecture in germinal center B cells and its alterations in lymphomagenesis. <i>Current Opinion in Genetics and Development</i> , 2022, 74, 101915.	1.5	2
329	<i>BCL10</i> Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. <i>Cancer Discovery</i> , 0, , OF1-OF20.	7.7	2
330	Untangling the Web of Lymphoma Somatic Mutations. <i>Cell</i> , 2017, 171, 270-272.	13.5	1
331	BCL6 Is Required for the Maintenance of Leukemia-Initiating Cells In Chronic Myeloid Leukemia. <i>Blood</i> , 2010, 116, 202-202.	0.6	1
332	LITAF, a BCL6 Target Gene, Regulates Autophagia in B Cells and Is Essential for T-Cell Dependent Humoral Responses. <i>Blood</i> , 2011, 118, 1391-1391.	0.6	1
333	DUSP6-Mediated Negative Feedback to Oncogenic Tyrosine Kinase Signaling Prevents Excessive Accumulation of ROS and Enables Leukemia Cell Survival. <i>Blood</i> , 2011, 118, 1479-1479.	0.6	1
334	Genome-Wide DNA Methylation Analysis Reveals Biological and Clinical Insights In Relapsed Childhood Acute Lymphoblastic Leukemia: A Report From The COG ALL Target Project. <i>Blood</i> , 2013, 122, 3736-3736.	0.6	1
335	Deep Sequencing Reveals Clonal Evolution Patterns and Mutation Events Associated With Relapse In B Cell Lymphomas. <i>Blood</i> , 2013, 122, 79-79.	0.6	1
336	BCL6 Orchestrates Tfh Differentiation Via Multiple Distinct Mechanisms. <i>Blood</i> , 2014, 124, 4137-4137.	0.6	1
337	IL2RA (CD25) Recruits Inhibitory Phosphatases to the Cell Membrane and Mediates Negative Feedback Control of STAT5 Signaling in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 788-788.	0.6	1
338	AICDA Introduces Epigenetic Plasticity in Germinal Center-Derived Lymphomas and Accelerates Lymphomagenesis. <i>Blood</i> , 2016, 128, 1045-1045.	0.6	1
339	BCL6 Is Critical for the Development of a Diverse Primary B Cell Repertoire.. <i>Blood</i> , 2009, 114, 91-91.	0.6	1
340	Development of Acute Megakaryoblastic Leukemia in Down Syndrome Is Associated with Sequential Epigenetic Changes That Target the Down Syndrome Critical Region on Chromosome 21,. <i>Blood</i> , 2011, 118, 3451-3451.	0.6	1
341	Gene Risk Scores Based on Expression of 6 Genes Quantitated by Nuclease Protection Assay in Formalin Fixed Paraffin-Embedded Tissue (FFPET) Specimens From CHOP and RCHOP Treated Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Predict Outcome: An ECOG and SWOG Study. <i>Blood</i> , 2011, 118, 87-87.	0.6	1
342	Conserved Transcriptional Deregulation Underlies GFI1 and ELANE Mutant Neutropenia. <i>Blood</i> , 2011, 118, 13-13.	0.6	1

#	ARTICLE	IF	CITATIONS
343	Negative Feedback Signaling Enables Leukemic Transformation by Oncogenic Tyrosine Kinases. Blood, 2012, 120, 1352-1352.	0.6	1
344	Combinatorial Targeting of BCL6 and Anti-Apoptotic Proteins in Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Blood, 2012, 120, 64-64.	0.6	1
345	Epigenetic Deregulation In Relapsed Acute Myeloid Leukemia. Blood, 2013, 122, 2499-2499.	0.6	1
346	Hsp90 at the Hub of Metabolic Homeostasis in Malignant B Cells. Blood, 2014, 124, 1764-1764.	0.6	1
347	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. Blood, 2015, 126, 435-435.	0.6	1
348	EZH2 Enables the Proliferation of Germinal Center B Cells and DLBCL through a Rb-E2F1 Positive Feedback Loop Involving Repression of CDKN1A. Blood, 2016, 128, 734-734.	0.6	1
349	Characterization of Complete Lncrnas Transcriptome Reveals Expression of Lncrnas As a Prognostic Factor and Linc-Smilo As a Potential Therapeutic Target in Multiple Myeloma. Blood, 2019, 134, 4323-4323.	0.6	1
350	Evolution of the Tumor Microenvironment throughout Progression and Transformation of EZH2 Mutant Follicular Lymphoma. Blood, 2021, 138, 446-446.	0.6	1
351	Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study. Blood, 2021, 138, 413-413.	0.6	1
352	Sirtuin 3 Inhibition Targets AML Stem Cells through Perturbation of Fatty Acid Oxidation. Blood, 2021, 138, 2240-2240.	0.6	1
353	Landscape and clinical significance of long noncoding <sc>RNAs</sc> involved in multiple myeloma expressed fusion transcripts. American Journal of Hematology, 2022, 97, .	2.0	1
354	The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma. Blood, 2020, 136, 34-34.	0.6	1
355	VII. Are lymphomas driven by epigenetic lesions?. Hematological Oncology, 2015, 33, 42-45.	0.8	0
356	Abstract LB014: Translational activation of ATF4 through mitochondrial anaplerotic metabolic pathways is required for DLBCL growth and survival. , 2021, , .		0
357	A BCL6 Target Gene Signature Predicts the Biological Behavior and Classification of Diffuse Large B-Cell Lymphoma.. Blood, 2006, 108, 616-616.	0.6	0
358	Antitumor Efficacy of the Purine-Scaffold Hsp90 Inhibitor PU-H71 in Diffuse Large-B Cell Lymphoma. Blood, 2008, 112, 602-602.	0.6	0
359	Genome-Wide Epigenetics in Myeloid Leukemias.. Blood, 2008, 112, sci-35-sci-35.	0.6	0
360	BCL6-Dependent Negative Regulation of Cell Cycle Checkpoint Regulators Enables Drug-Resistance in Ph+ Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 765-765.	0.6	0

#	ARTICLE	IF	CITATIONS
361	Genome-Wide Methylation Analysis of Primary Mantle Cell Lymphomas Identifies Novel Gene Targets for Epigenetic Drug Therapy.. Blood, 2009, 114, 673-673.	0.6	0
362	DNA Methylation Profiling Predicts Clinical Outcomes and Reveals Unique Insights Into the Molecular Complexity of Acute Myeloid Leukemia.. Blood, 2009, 114, 707-707.	0.6	0
363	Promoter Hypermethylation in MLL-r Leukemia: Biology and Therapeutic Targeting.. Blood, 2009, 114, 3472-3472.	0.6	0
364	STAT3, Constitutively Activated In ABC-Like DLBCL, Regulates Expression of the Prognostic Factor Cyclin D2. Blood, 2010, 116, 705-705.	0.6	0
365	Chemosensitization of Diffuse Large B Cell Lymphoma by Demethylating Nucleoside Analogues. Blood, 2011, 118, 1617-1617.	0.6	0
366	Pre-B Cell Receptor-Mediated Activation of BCL6 Induces Pre-B Cell Quiescence Through Transcriptional Repression of MYC. Blood, 2011, 118, 1406-1406.	0.6	0
367	Identification of LMO2 Transcriptome and Interactome in Diffuse Large B-Cell Lymphoma by Integrated Experimental and Computational Approach. Blood, 2011, 118, 438-438.	0.6	0
368	A Role for BCL6 in the Higher-Order Organization of Genes in DLBCL. Blood, 2011, 118, 558-558.	0.6	0
369	BACH2 Mediates Early B Cell Differentiation and Oncogene-Induced Senescence in Acute Lymphoblastic Leukemia. Blood, 2011, 118, 562-562.	0.6	0
370	Epigenetic Profiling of Primary DLBCLs Reveals Novel DNA Methylation-Based Clusters and New Underlying Mechanisms of Lymphomagenesis. Blood, 2011, 118, 556-556.	0.6	0
371	Genomewide Detection of Genes Targeted by Aberrant Somatic Hypermethylation in Lymphoma,. Blood, 2011, 118, 3474-3474.	0.6	0
372	High-Resolution Chromatin Immunoprecipitation (ChIP) Sequencing Identifies Novel Binding Targets and Prognostic Role for SOX11 in Mantle Cell Lymphoma. Blood, 2011, 118, 585-585.	0.6	0
373	MiR-181a Is a Master Regulator of the Nuclear Factor- κ B Signaling Pathway in Diffuse Large B Cell Lymphoma. Blood, 2012, 120, 417-417.	0.6	0
374	BACH2 Is Required for Pre-B Cell Receptor Checkpoint Control and p53-Dependent Tumor Surveillance. Blood, 2012, 120, 1300-1300.	0.6	0
375	H2.0-Like Homeobox (HLX) Induces Unlimited Clonogenicity, Blocks Differentiation, and Cooperates with FLT3-ITD in the Induction of Acute Myeloid Leukemia. Blood, 2012, 120, 651-651.	0.6	0
376	Targeting BCL6-Mediated Drug-Resistance in High-Risk Childhood ALL. Blood, 2012, 120, 776-776.	0.6	0
377	Next Gen Dissection of Gfi1 Dependent Transcriptome in Myeloid Progenitors Reveals Global Control of Multiple Transcriptional Programs Including Coding and Non Coding RNAs. Blood, 2012, 120, 111-111.	0.6	0
378	Enhancer Profiling Reveals SOX9 As a Novel Transcription Regulator of B Cell Activation and DLBCL Transformation. Blood, 2012, 120, 527-527.	0.6	0

#	ARTICLE	IF	CITATIONS
379	Lineage, Fusion Partner and Age Differences in the Methylome of MLL-r Leukemias. <i>Blood</i> , 2012, 120, 3506-3506.	0.6	0
380	High-Resolution Genomic Methylation Analysis Using Next Generation Sequencing Identifies Loci Associated With Differential Prognosis In Mantle Cell Lymphoma Patients Treated With Bortezomib + DA-EPOCH-R. <i>Blood</i> , 2013, 122, 3760-3760.	0.6	0
381	The Bcl6 RD2 Domain Is Essential For Pre-Germinal Center B Cell Development. <i>Blood</i> , 2013, 122, 783-783.	0.6	0
382	Inhibitory Receptors and Phosphatases Enable Oncogenic Tyrosine Kinase Signaling In B Cell Lineage Leukemia. <i>Blood</i> , 2013, 122, 229-229.	0.6	0
383	Identification Of BCL6 As a Therapeutic Target In MLL-Rearranged ALL. <i>Blood</i> , 2013, 122, 72-72.	0.6	0
384	Erk and Stat5 Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 787-787.	0.6	0
385	PTEN Is Essential for Normal Cytokine Signaling and Oncogenic Transformation of Pre-B Cells. <i>Blood</i> , 2014, 124, 262-262.	0.6	0
386	BCL6 Enables RAS-Mediated Pre-B Cell Transformation in Childhood Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 3570-3570.	0.6	0
387	Conditional Loss of Dnmt3a Results in Myeloproliferation and Liver-Specific Myeloid Expansion. <i>Blood</i> , 2014, 124, 364-364.	0.6	0
388	Mirna-181a expression Lead to Longer Animal Survival and Slower Tumor-Growth Rate in Diffuse Large B-Cell Lymphoma Xenograft Models. <i>Blood</i> , 2014, 124, 2963-2963.	0.6	0
389	BACH2 promotes Lineage-Specific Fate Decisions in BCR-ABL1-Driven Leukemia. <i>Blood</i> , 2014, 124, 513-513.	0.6	0
390	Harnessing Negative B Cell Selection to Overcome Drug-Resistance in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 792-792.	0.6	0
391	Self-Enforcing Feedback Activation Between BCL6 and Tonic Pre-B Cell Receptor Signaling in Acute Lymphoblastic Leukemia. <i>Blood</i> , 2014, 124, 284-284.	0.6	0
392	Msi2 Maintains the MLL Leukemia Stem Cell Regulatory Program. <i>Blood</i> , 2014, 124, 836-836.	0.6	0
393	DNA Hydroxymethylation Profiling Reveals That WT1 Mutations Result in Loss of TET2 Function in Acute Myeloid Leukemia. <i>Blood</i> , 2014, 124, 365-365.	0.6	0
394	The Significance of GADD45A Promoter DNA Hypermethylation in AML: Association with IDH1/2 and TET2 Mutation. <i>Blood</i> , 2014, 124, 69-69.	0.6	0
395	Hyperactive Ptpn11 Mutations Alters Leukemic Stem Cell Frequency through Mcl-1 Overexpression. <i>Blood</i> , 2014, 124, 3565-3565.	0.6	0
396	Whole-Genome Epigenomic Analysis in Multiple Myeloma Reveals DNA Hypermethylation of B-Cell Specific Enhancers. <i>Blood</i> , 2014, 124, 2032-2032.	0.6	0

#	ARTICLE	IF	CITATIONS
397	Transcriptome Sequencing Reveals Thousands of Novel Long Non-Coding RNAs in B-Cell Lymphoma. Blood, 2015, 126, 2427-2427.	0.6	0
398	A Chromatin Reader That Acts As a Key to Lock in and Coordinate Recruitment of Transcription Factors and a Novel Polycomb Complex to Bivalent Chromatin Thus Driving Formation of Germinal Centers and B-Cell Lymphomas. Blood, 2015, 126, 434-434.	0.6	0
399	Integrated DNA/RNA Profiling for Somatic Alterations in Adult B-Cell ALL. Blood, 2015, 126, 1422-1422.	0.6	0
400	Targeted Activation of B Cell Autoimmunity Checkpoints in Acute Lymphoblastic Leukemia. Blood, 2015, 126, 3716-3716.	0.6	0
401	Identification of BCL6 As a Therapeutic Target in RAS-Driven Acute Lymphoblastic Leukemia. Blood, 2015, 126, 556-556.	0.6	0
402	Crebbp Mutations Disrupt Dynamic Enhancer Acetylation in B-Cells, Enabling HDAC3 to Drive Lymphomagenesis. Blood, 2016, 128, 735-735.	0.6	0
403	Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia. Blood, 2016, 128, 599-599.	0.6	0
404	Hypermethylation of GADD45A Defines a Methylation Profile Distinct to Mutant IDH1/2, and Correlates with More Aggressive AML. Blood, 2016, 128, 2877-2877.	0.6	0
405	RNA Interference Screen Implicates TNFAIP3 and FOXO1 in MALT1 Inhibition Resistance. Blood, 2016, 128, 837-837.	0.6	0
406	Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia. Blood, 2016, 128, 1048-1048.	0.6	0
407	Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-Rearranged Acute Lymphoblastic Leukemia. Blood, 2016, 128, 907-907.	0.6	0
408	BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation. Blood, 2016, 128, 438-438.	0.6	0
409	RNA Binding Protein Syncrip Regulates the Leukemia Stem Cell Program. Blood, 2016, 128, 739-739.	0.6	0
410	m6a Regulates Differentiation State and mRNA Translation in Myeloid Leukemia. Blood, 2017, 130, 791-791.	0.6	0
411	HSP90 Facilitates Oncogene-Induced Metabolic Reprogramming in B-Cell Lymphomas. Blood, 2017, 130, 645-645.	0.6	0
412	Heat Shock Factor 1 Reprograms the DLBCL Microenvironment to Evade Immune Surveillance and Support Tumor Growth. Blood, 2018, 132, 2854-2854.	0.6	0
413	Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling. Blood, 2019, 134, 393-393.	0.6	0
414	Mapping MALT1 Signaling Connectivity Unveils Novel B-Cell Feedback Mechanisms Directing Assembly of Potent Anti-Lymphoma Regimens. Blood, 2019, 134, 173-173.	0.6	0

#	ARTICLE	IF	CITATIONS
415	Rationale for Targeting BCL6 in MLL-Rearranged B-ALL. Blood, 2019, 134, 1239-1239.	0.6	0
416	Complex Structural Variation Associated with Enhancer Hijacking and Loss of Tumor Suppressors in Mantle Cell Lymphoma. Blood, 2021, 138, 675-675.	0.6	0
417	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
418	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
419	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
420	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
421	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
422	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
423	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0
424	Targeted detection and quantitation of histone modifications from 1,000 cells. , 2020, 15, e0240829.		0